Merck strives to commercialize our products in a way that both develops our business and meets local needs responsibly and efficiently.

Through our worldwide differential-pricing framework, we are committed to making our medicines and vaccines more affordable to more people by applying a differential-pricing approach that takes into account level of economic development, channel and public health need.

For example, in the developing world, Merck offers ROTATEQ^® (Rotavirus Vaccine, Live, Oral, Pentavalent) and GARDASIL^® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] at an access price that is significantly less than the price of these vaccines in developed markets. The access price is exclusive to the public sector of GAVI-eligible countries, meeting the needs of the developing world by facilitating access to these innovative vaccines in the poorest countries, while making sure they remain affordable and sustainable in the long term.

We believe that our pricing approach contributes to wider access to our vaccines, while taking into account our need to continue investing in vaccine research, development and production. In more developed middle-income countries, Merck provides our vaccines at tiered prices in relation to a country's ability to pay.

We also invest in activities to increase knowledge among patients and physicians, because we believe that providing support to third-party medical, scientific and patient organizations is an important way to improve health and advance patient care. Learn more.

Learn more about pricing of our products.